Cost · checked August 2026
No 1-month price
No price for one month with no commitment appears on their public pages. Every figure they do publish is below.
| Plan | Per month | Charged today |
|---|---|---|
| Microdose GLP-1 Rx, 12-week subscription · advertised | $179 | $537 |
Noom's own sentence, from its cost page on 2026-08-31: "Noom GLP-1Rx Program: A low-dose semaglutide plan starting at $79 for the first 4-week supply, then $537 every 12 weeks ($179 per month)." The multiplication holds — $179 x 3 is $537 — but a twelve-week subscription is not a quarter. Fifty-two weeks hold 4.33 of them, so a year is thirteen $179 payments, $2,327, rather than the twelve the phrase "per month" implies. The full-dose plan on the same page reads "Starts at $129 for the initial 4-week supply, then $279 per month" and states no renewal cycle at all; a table further down the page prices the full-dose tirzepatide program at "$149 initial 4-week supply, $299/month".
| Plan | Per month | Charged today |
|---|---|---|
| Microdose GLP-1 Rx Plus, 12-week subscription | $199 | $597 |
"Noom GLP-1Rx Plus Program: A low-dose tirzepatide plan starting at $99 for the first 4-week supply, then $597 every 12 weeks ($199 per month)." Same cadence, same arithmetic: $199 x 3 is $597 exactly, and 4.33 of those charges fill a 52-week year, which is thirteen $199 payments rather than twelve.
Noom prices in weeks and talks in months. The microdose semaglutide plan starts at $79 for the first four-week supply and then, in Noom's own words, costs "$537 every 12 weeks ($179 per month)." The multiplication is honest — $179 times three is $537 on the nose. The unit isn't. Twelve weeks is 84 days, and a 52-week year holds 4.33 of them, so you get billed $537 four and a third times. That is thirteen $179 payments a year, $2,327, against the $2,148 that "per month" gets a reader to.
The tirzepatide microdose runs the same way: $99 for the first four weeks, then $597 every 12 weeks, which Noom glosses as $199 a month. Thirteen of those is $2,587. And the very first period is odder still, because the footnote defining it reads "Initial 3 week subscription and 4 weeks of medication" — three weeks of subscription against four weeks of medicine, out of step before you have taken a dose.
The full-dose programs are quoted without a cycle at all: "Starts at $129 for the initial 4-week supply, then $279 per month" for semaglutide and $149 then $299 for tirzepatide. Noom's home page carries the same footnote grammar for a $349 plan — "$349 per month plus tax for 12 week subscription thereafter" — so on Noom's own pages a per-month figure is what a twelve-week subscription costs, divided by three.
Then there's the starting price, which depends on which sentence you land on. The home page banner says $49. The blog post's top footnote says $49. The same blog post's numbered footnote at the bottom says $79. The body and the summary table both say $79. Two versions of one footnote, one page, one day. The two footnotes even disagree about when the pricing took effect: one says "effective as of March 31, 2026" and the other "effective as of July 27, 2026."
The rest of the review — what the service is like and who should skip it — is on the Noom review. Prices move; this page was read August 2026, and the company's own site is the current source.
To see every plan above priced out line by line — the rate, any required membership, any published consultation fee, and what a prepay term charges today — use the real cost calculator. It reads the same ladder this page does, so the two cannot disagree.
Noom is not a partner. We link to them from the review and earn nothing from it.
More reviews on the index; the rules behind them are on how we review, written by Kevin Turner.